Payment overview · 2025
General Payments
$89.62
4 reported records · 4 companies
Healthcare provider profile · identity verified
Vincent Dalessandro, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CHESTERLAND, OH · NPI 1023000221
Verified facts
What the public records show
CMS Open Payments records show Vincent Dalessandro, DO received $89.62 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.68 | 32.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.69 | 29.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.25 | 21.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.00 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.62 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 868 | 323 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 199 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 182 |
| Losartan Potassium | Losartan Potassium | 449 | 172 |
| Lisinopril | Lisinopril | 376 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 121 |
| Omeprazole | Omeprazole | 286 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 97 |
| Gabapentin | Gabapentin | 249 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 80 |
| Trazodone Hcl | Trazodone Hcl | 201 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 69 |
| Eliquis | Apixaban | 180 | 58 |
| Jardiance | Empagliflozin | 159 | 53 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 157 | 55 |
| Metformin Hcl Er | Metformin Hcl | 153 | 68 |
| Metformin Hcl | Metformin Hcl | 147 | 53 |
| Allopurinol | Allopurinol | 138 | 52 |
| Simvastatin | Simvastatin | 128 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 67 |
| Sertraline Hcl | Sertraline Hcl | 120 | 53 |
| Ezetimibe | Ezetimibe | 117 | 48 |
| Cephalexin | Cephalexin | 114 | 89 |
| Finasteride | Finasteride | 110 | 44 |
| Furosemide | Furosemide | 110 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 49 |
| Meloxicam | Meloxicam | 110 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 63 |
| Montelukast Sodium | Montelukast Sodium | 108 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 50 |
| Potassium Chloride | Potassium Chloride | 100 | 36 |
| Prednisone | Prednisone | 98 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 36 |
| Alendronate Sodium | Alendronate Sodium | 94 | 46 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 92 | 71 |
| Synthroid | Levothyroxine Sodium | 87 | 31 |
| Donepezil Hcl | Donepezil Hcl | 85 | 29 |
| Famotidine | Famotidine | 84 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 32 |
| Spironolactone | Spironolactone | 79 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 37 |
| Glimepiride | Glimepiride | 73 | 27 |
| Mirtazapine | Mirtazapine | 70 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 30 |
| Amoxicillin | Amoxicillin | 64 | 46 |
| Ozempic | Semaglutide | 61 | 21 |
| Carvedilol | Carvedilol | 60 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 27 |
| Azelastine Hcl | Azelastine Hcl | 55 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 20 |
| Warfarin Sodium | Warfarin Sodium | 55 | 20 |
| Atenolol | Atenolol | 54 | 24 |
| Buspirone Hcl | Buspirone Hcl | 53 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 24 |
| Meclizine Hcl | Meclizine Hcl | 49 | 23 |
| Azithromycin | Azithromycin | 48 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Memantine Hcl | Memantine Hcl | 44 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 30 |
| Lovastatin | Lovastatin | 40 | 14 |
| Felodipine Er | Felodipine | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 16 |
| Methocarbamol | Methocarbamol | 37 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Valsartan | Valsartan | 36 | 24 |
| Mounjaro | Tirzepatide | 35 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 33 | 11 |
| Colchicine | Colchicine | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Hydrocortisone | Hydrocortisone | 30 | 26 |
| Mupirocin | Mupirocin | 30 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 12 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Torsemide | Torsemide | 26 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.62 · 4 records | Otsuka America Pharmaceutical, Inc. | ELIQUIS, JARDIANCE, NURTEC ODT, REXULTI, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error